INFECTIOUS DISEASE CONTROL IN A WORLD THAT NEEDS IT

The growing world population and climate change give rise to increasing incidences and rapidly spreading infectious diseases.

ExeVir develops novel antibody therapies capable of preventing and treating current public health threats and responding to future outbreaks with speed and agility.

A UNIQUE ANTIBODY PLATFORM

Our modular platform technology uses camelid antibody fragments (VHH) as building blocks to create new therapeutic compounds. These constructs are very stable, and cost-effective and easy to produce. They can bind multiple – often well-conserved – epitopes on a bacterial cell or viral particle, conveying an advantage against emerging disease variants and subtypes.

FIGHTING INFECTIOUS DISEASES IN A CHANGING WORLD

Based on our unique modular and multi-specific single domain antibody (VHH) platform, we are building a pipeline of antibody therapies. We aim to tackle the growing impact of infectious diseases, with an initial focus on COVID-19 and dengue, to help the most vulnerable patients, including the immunocompromised.

ABOUT EXEVIR

We are a clinical stage company and have demonstrated the ability to fast-track antibody drug development. Building on the extensive experience of our management team and support from a strong international investor syndicate, we strive to rapidly advance our new drug candidates through clinical development and meet the unmet needs of patients.

IMPROVING PATIENT LIVES TOGETHER

To mature our current product portfolio and leverage the potential of our VHH platform in other infectious diseases, we are looking for strategic partners for the co-development of novel therapeutics and investors to participate in upcoming funding rounds.

Are you interested in joining forces with us?